DE1070632B - Process for the preparation of 2-alkyl and 2-aralkylide derivatives of 17ec-lower-alkyl-z! 4-androstene-17 /? Ol-3-ones and 17a-lower alkyl-androstane (or testane) -17 ^ -01-3-ones - Google Patents
Process for the preparation of 2-alkyl and 2-aralkylide derivatives of 17ec-lower-alkyl-z! 4-androstene-17 /? Ol-3-ones and 17a-lower alkyl-androstane (or testane) -17 ^ -01-3-onesInfo
- Publication number
- DE1070632B DE1070632B DENDAT1070632D DE1070632DA DE1070632B DE 1070632 B DE1070632 B DE 1070632B DE NDAT1070632 D DENDAT1070632 D DE NDAT1070632D DE 1070632D A DE1070632D A DE 1070632DA DE 1070632 B DE1070632 B DE 1070632B
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- methyl
- ethyl
- ecm
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 10
- QZLYKIGBANMMBK-DYKIIFRCSA-N 5β-androstane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-DYKIIFRCSA-N 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 9
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 8
- -1 benzyl compound Chemical class 0.000 claims description 8
- 230000000875 corresponding Effects 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 229960003604 Testosterone Drugs 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 claims description 3
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 229910052570 clay Inorganic materials 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims description 2
- 239000012044 organic layer Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims 2
- 210000003298 Dental Enamel Anatomy 0.000 claims 2
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000005712 crystallization Effects 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 210000003608 Feces Anatomy 0.000 claims 1
- WYZDXEKUWRCKOB-YDSAWKJFSA-N Mestanolone Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 WYZDXEKUWRCKOB-YDSAWKJFSA-N 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 230000002152 alkylating Effects 0.000 claims 1
- 150000001440 androstane derivatives Chemical class 0.000 claims 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Inorganic materials [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims 1
- IFNNXDFBUBKSAU-UHFFFAOYSA-L barium(2+);palladium;sulfate Chemical compound [Pd].[Ba+2].[O-]S([O-])(=O)=O IFNNXDFBUBKSAU-UHFFFAOYSA-L 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001805 chlorine compounds Chemical class 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- WQPDQJCBHQPNCZ-UHFFFAOYSA-N cyclohexa-2,4-dien-1-one Chemical compound O=C1CC=CC=C1 WQPDQJCBHQPNCZ-UHFFFAOYSA-N 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 239000010871 livestock manure Substances 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000001548 androgenic Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- FGPGANCDNDLUST-CEGNMAFCSA-N Ethyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 FGPGANCDNDLUST-CEGNMAFCSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000001195 anabolic Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical compound ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
PATENTAMTPATENT OFFICE
KL. 12 ο 25/04KL. 12 ο 25/04
S52137IVb/12oS52137IVb / 12o
BEKANNTMACHDMC DERANMELDUNG UND AUSGABE DER AUSLEGESCHHIFT: 10. DEZEMBER 1959ANNOUNCEMENTDMC LOGIN AND ISSUE OF THE DISPLAY: DECEMBER 10, 1959
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung neuer androgenwirksamer Hormone, die 2-Alkyl- und 2-Aralkylderivate von 17 α-niedrig-Alkyltestosteronen und ^a-niedrig-Alkyldihydrotestosteronen sind. Ebenso betrifft die vorliegende Erfindung die Herstellung aktiver Hormone vom Androgentyp, welche die entsprechenden 3-Oxy-2-alkyl- und -2-aralkylderivate des 17 α-niedrig-Alkyltestosterons und -dihydro test osterons sind. Die neuen erfindungsgemäß hergestellten Androgene unterscheiden sich in ihren Eigenschaften von ähnlichen Verbindungen, die keinen Substituenten in der 2-Stellung enthalten, insbesondere dadurch wesentlich, daß das Verhältnis von anabolischer zu androgener Wirkung ein höheres ist als bei bisher bekannten Verbindungen, wie z. B. Methyltestosteron. Weiterhin besitzen sie eine größere antiöstrogene Wirkung als Testosteron und Dihydro testosteron, und sie verhindern das Wachstum von Brustkrebs bei Ratten wesentlich stärker als Dihydro testosteron.The present invention relates to a method for Production of new androgenic hormones, the 2-alkyl and 2-aralkyl derivatives of 17 α-lower alkyl testosterones and ^ a-lower alkyl dihydrotestosterones are. Likewise, the present invention relates to the production of active hormones of the androgen type, which the corresponding 3-oxy-2-alkyl and -2-aralkyl derivatives the 17 α-lower alkyl testosterone and dihydro test osterone are. The new androgens produced according to the invention differ in their properties of similar compounds which do not contain any substituents in the 2-position, in particular as a result of which that the ratio of anabolic to androgenic effect is higher than with previously known compounds, such as B. Methyltestosterone. They also have a greater anti-estrogenic effect than testosterone and dihydro testosterone, and they are much more effective at preventing breast cancer from growing in rats as dihydro testosterone.
Das erfindungsgemäße Verfahren zur Herstellung von 2-Alkyl- und 2-Aralkylderivaten von 17a-niedrig-Alkyl-J4-androsten-17ß-ol-3-onen und 17 α-niedrig-Alkylandrostan-(bzw.-testan)-17/3-ol-3-onen ist nun dadurch gekennzeichnet, daß man ein 17a-niedrig-Alkyl-J4-androsten-17/?-ol-3-on oder 17α-niedrig-Alkylandrostan-17/i-ol- »5 3-on in bekannter Weise mit Äthylformiat umsetzt, das erhaltene Oxymethylenderivat in bekannter Weise mit einem Alkyl- oder Aralkyljodid umsetzt und aus dem erhaltenen 2-Alkyl-2'-formyl- bzw. 2-Aralkyl-2'-formylderivat mit einer milden Base Kohlenmonoxyd abspaltet bzw. daß man das erhaltene 2-Alkyl- oder 2-Aralkylderivat eines 17a-niedrig-Alkyl-/l*-androsten-17/3-ol-3-ons in Gegenwart eines Hydrierungskatalysators in bekannter Weise hydriert.The process according to the invention for the preparation of 2-alkyl and 2-aralkyl derivatives of 17a-low-alkyl- I 4 -androsten-17ß-ol-3-ones and 17 α-low-alkylandrostane (or testane) -17 / 3-ol-3-ones is characterized in that a 17α-lower alkyl-I 4 -androsten-17 /? - ol-3-one or 17α-lower-alkylandrostan-17 / i-ol- »5 3-one is reacted in a known manner with ethyl formate, the oxymethylene derivative obtained is reacted in a known manner with an alkyl or aralkyl iodide and the 2-alkyl-2'-formyl or 2-aralkyl-2'-formyl derivative obtained is converted with a mild base Carbon monoxide is split off or the 2-alkyl- or 2-aralkyl derivative of a 17a-lower alkyl- / l * -androsten-17/3-ol-3-one obtained is hydrogenated in a known manner in the presence of a hydrogenation catalyst.
Die erfindungsgemäß hergestellten Verbindungen entsprechen den folgenden Formeln: OHThe compounds prepared according to the invention correspond to the following formulas: OH
Verfahren zur HerstellungMethod of manufacture
von 2-Alkyl- und 2-Aralkylderivatenof 2-alkyl and 2-aralkyl derivatives
von 17a-niedrig-Alkyl-zl4-androsten-of 17a-lower-alkyl-zl4-androsten-
17/3-ol-3-onen und 17 α-niedrig-Alkyl-17/3-ol-3-ones and 17 α-lower alkyl
androstan- (bzw. -testan) -17/3-ol-3-onenandrostan- (or -testan) -17 / 3-ol-3-ones
Anmelder:
Syntex S.A., Mexiko (Mexiko)Applicant:
Syntex SA, Mexico (Mexico)
Vertreter: Dr. W. Schalk, Dipl.-Ing. P. Wirth,Representative: Dr. W. Schalk, Dipl.-Ing. P. Wirth,
Dipl.-Ing. G. E. M. DannenbergDipl.-Ing. G. E. M. Dannenberg
und Dr. V. Schmied-Kowarzik, Patentanwälte,and Dr. V. Schmied-Kowarzik, patent attorneys,
Frankfurt/M., Große Eschenheimer Str. 39Frankfurt / M., Große Eschenheimer Str. 39
Beanspruchte Priorität:
Mexiko vom 7. Februar 1956Claimed priority:
Mexico 7 February 1956
Dr. Howard J. Ringold und Dr. George Rosenkranz,Dr. Howard J. Ringold and Dr. George Rosary,
Mexiko (Mexiko),
sind als Erfinder genannt wordenMexico (Mexico),
have been named as inventors
In diesen Formeln steht R für eine Alkylgruppe, vor- «o zugsweise eine niedrige Alkylgruppe mit weniger als 7 Kohlenstoffatomen, wie eine Methyl-, Äthyl- oder Propylgruppe, oder für eine Aralkylgruppe, wie die Benzylgruppe. R' steht für Wasserstoff oder für eine Acylgnippe, wie sie bei veresterten Steroidalkoholen üblicherweise auftritt; meistens solche, die sich von Kohlenwasserstoffcarbonsäuren mit weniger als 12 Kohlenstoffatomen ableiten, wie z. B. Essigsätire^ Propionsäure, Cyclopentylpropionsäure, Benzoesäure usw. X steht für eine gesättigte C4-, C8-Bindung oder eine Doppelbindung. R2 steht für eine niedrige Alkylgruppe von weniger als 7 Kohlenstoffatomen, wie die Methyl-, Äthyloder Propylgruppe.In these formulas, R stands for an alkyl group, preferably a lower alkyl group with fewer than 7 carbon atoms, such as a methyl, ethyl or propyl group, or an aralkyl group, such as the benzyl group. R 'stands for hydrogen or for an acyl group, as it usually occurs in the case of esterified steroidal alcohols; mostly those derived from hydrocarbon carboxylic acids with fewer than 12 carbon atoms, such as. B. Essigsätire ^ propionic acid, cyclopentylpropionic acid, benzoic acid, etc. X represents a saturated C 4 , C 8 bond or a double bond. R 2 represents a lower alkyl group of fewer than 7 carbon atoms, such as the methyl, ethyl or propyl group.
Das erfindungsgemäße Verfahren verläuft entsprechend den folgenden Gleichungen:The method according to the invention proceeds accordingly the following equations:
90» 6M/43190 »6M / 431
OHOH
O=O =
ÄthylformiatEthyl formate
OHOH
TonerdeClay
OHOH
...R2... R2
HydrierungskatalysatorHydrogenation catalyst
OHOH
OHOH
Reduktion NatriumborhydridReduction of sodium borohydride
, In den obigen Gleichungen stehen R, R2 und X wie oben definiert., In the above equations, R, R 2 and X are as defined above.
Bei der Durchführung der ersten Stufe des obigen Verfahrens wird die Ausgangsverbindung, welche ein 17 α-niedrig-Alkyltestosteronderivat sein kann, z. B. Methyloder Äthyltestosteron oder die entsprechenden, in 4(5)-Stellung gesättigten Derivate der Alloreihe, wie das 17a-Methyl- oder ^a-Äthylandrostan-^/J-ol-S-on, in einem organischen Lösungsmittel, wie wasserfreiem Benzol, suspendiert und dann mit Äthylformiat und Natriumhydrid gemischt. Die Reaktionsmischung wird dann längere Zeit, etwa 1 Tag, bei Zimmertemperatur unter Stickstoff gehalten. Anschließend wird das Hydrid durch vorsichtige Zugabe von Methanol. zersetzt und kaltes Wasser zur Bildung von zwei Schichten zugegeben, wobei sich das gewünschte Produkt in der wäßrigen Schicht in Form des Natriumsalzes befindet. Dle"waBnge Schicht wird abgetrennt, gewaschen und mit einer verdünnten Mineralsäure; wie Salzsäure; angesäuert und mit einem organischen Lösungsmittel, wie Methylenchlorid, extrahiert. Aus der organischen Lösung wird die gewünschte 2-Oxymethylcnverbindung durch Eindampfen zur Trockne und Umkristallisieren erhalten.In carrying out the first step of the above process, the starting compound, which is a 17 may be α-lower alkyl testosterone derivative, e.g. B. methyl or Ethyl testosterone or the corresponding derivatives of the allo series saturated in the 4 (5) position, such as that 17a-methyl- or ^ a-Äthylandrostan - ^ / J-ol-S-one, in an organic solvent such as anhydrous benzene, and then with ethyl formate and suspended Sodium hydride mixed. The reaction mixture is then left for a long time, about 1 day, at room temperature kept under nitrogen. Then the hydride is made by carefully adding methanol. decomposed and cold water was added to form two layers, the desired product in the aqueous Layer is located in the form of the sodium salt. The walls Layer is separated, washed and washed with a dilute mineral acid; like hydrochloric acid; acidified and extracted with an organic solvent such as methylene chloride. The organic solution becomes the desired 2-oxymethyl compound by evaporation obtained to dryness and recrystallization.
Zur Durchführung der zweiten Stufe des erfindungsgemäßen Verfahrens wird die 2-Oxymethylenverbindung in einer Suspension in einem organischen Lösungsmittel mit Natriumhydrid so wie mit einem Alkyl- oder Aralkyljodid behandelt, vorzugsweise einem niedrigen Alkyljodid oder Benzyljodid.The 2-oxymethylene compound is used to carry out the second stage of the process according to the invention in suspension in an organic solvent with sodium hydride as well as with an alkyl or aralkyl iodide treated, preferably a lower alkyl iodide or benzyl iodide.
Die Behandlung wird vorteilhafterweise unter Rückflußbedingungen und in einer Stickstoff- oder Wasserstoffatmosphäre durchgeführt. Die Reaktion wird längere Zeit, etwa 72 Stunden, unter aufeinanderfolgenden Zugaben von Jodid nach jeweils 24stündigen Intervallen durchgeführt. Die Mischung wird abgekühlt mit einer verdünnten Base gewaschen, um nicht umgesetztes Material zu entfernen, und das entstandene 2-Alkyl- oder 2-Aralkyl-2'-formylderivat aus der organischen Schicht durch Eindunsten und Umkristallisieren gewonnen. The treatment is advantageously carried out under reflux conditions and in a nitrogen or hydrogen atmosphere carried out. The reaction takes longer, about 72 hours, with successive additions of iodide every 24 hour intervals carried out. The mixture is cooled and washed with a dilute base to remove any unreacted To remove material, and the resulting 2-alkyl- or 2-aralkyl-2'-formyl derivative from the organic Layer obtained by evaporation and recrystallization.
Die so hergestellten 2-Alkyl- oder 2-Aralkyl-2'-formylderivate werden mit einer milden Base, vorzugsweise aktivierter Tonerde (vom chromatographischen Typ) von alkalischer Reaktion behandelt. Bei dieser Behandlung wird eine benzolische Lösung der Verbindung durch eine Tonerdesäule durchgeführt und nach etwa 1 Tag dasThe 2-alkyl- or 2-aralkyl-2'-formyl derivatives so prepared are treated with a mild base, preferably activated alumina (of the chromatographic type) of treated with an alkaline reaction. In this treatment, a benzene solution of the compound is replaced by a Alumina column carried out and after about 1 day the
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
DE1070632B true DE1070632B (en) | 1959-12-10 |
Family
ID=595494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DENDAT1070632D Pending DE1070632B (en) | Process for the preparation of 2-alkyl and 2-aralkylide derivatives of 17ec-lower-alkyl-z! 4-androstene-17 /? Ol-3-ones and 17a-lower alkyl-androstane (or testane) -17 ^ -01-3-ones |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE1070632B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1189545B (en) * | 1961-11-23 | 1965-03-25 | Ormonoterapia Richter S P A | Process for the production of 2alpha-methylandrostane derivatives |
-
0
- DE DENDAT1070632D patent/DE1070632B/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1189545B (en) * | 1961-11-23 | 1965-03-25 | Ormonoterapia Richter S P A | Process for the production of 2alpha-methylandrostane derivatives |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1793732C3 (en) | Process for the preparation of 17- (acyloxy- or alkoxy) -polyunsaturated gonane or 8-isogonane derivatives. Eliminated from: 1593382 | |
CH517725A (en) | 7-Alpha steroids | |
DE1468410A1 (en) | Process for the preparation of 16-methylene steroids | |
DE1070632B (en) | Process for the preparation of 2-alkyl and 2-aralkylide derivatives of 17ec-lower-alkyl-z! 4-androstene-17 /? Ol-3-ones and 17a-lower alkyl-androstane (or testane) -17 ^ -01-3-ones | |
DE2409971C3 (en) | 5-cholesteric derivatives and process for their preparation | |
DE1263000B (en) | New process for the production of mixtures of delta 1,3,5 (10) -3-oxysteroids and delta 1,3,5 (10) 9 (11) -3-oxysteroids or of delta 1,3,5 (10) -3 oxysteroids | |
CH537913A (en) | Delta5 10-3-keto-19-norsteroids | |
DE1252679B (en) | Process for the preparation of zlM.5 (10) -A-homo-oestratrien-3-one derivatives | |
DE1187238B (en) | Method of making steroids | |
AT233184B (en) | Process for the preparation of 3-oxo-Δ <1,4> steroids | |
DE1264441B (en) | Process for the production of 17alpha-AEthynyl-delta 5 (10-19-nor-androsten-17beta-ol-3-one and 17alpha-AEthynil-19-nor-testosterone and its esters | |
CH495965A (en) | 16alpha-alkyl estrane derivs | |
DE1593448C (en) | 13beta-ethyl-gon-4-en-3-one-thioketals, their preparation and agents containing them | |
AT270086B (en) | Process for the production of new 9β, 10α-steroids | |
AT257060B (en) | Process for the preparation of new 3-enol ethers of the 6-methyl-3-oxo-Δ <4> -steroids of the androstane, 19-norandrostane, pregnane and 19-norpregnane series | |
AT279820B (en) | METHOD FOR PRODUCING NEW STEROID COMPOUNDS | |
DE1493143A1 (en) | New 5,10,17-trihydroxyoestrane compounds and processes for their preparation | |
DE1250433B (en) | Process for the production of Zl2 4 steroids of the Androstan- 19-Norandrostan Pregnan or 19 Norpregnan series | |
DE1193043B (en) | Process for the preparation of 3-AEthylenedioxy-androstan-1-one derivatives | |
DE1161265B (en) | Process for the production of 3-oxo-í¸-steroids | |
DE1250435B (en) | ||
DE1243682B (en) | Process for the preparation of therapeutically active steroid compounds | |
CH374656A (en) | Process for the preparation of 6-fluoro-3-oxo-1,4-steroids | |
DE1101415B (en) | Process for the preparation of 6ª ‡ -Methyl-17ª ‡ -acetoxy-4-pregnen-3, 20-dione | |
DE1300942B (en) | Process for the preparation of 19-hydroxy-ª € 5-androstene or 19-hydroxy-ª € 5-pregnancy derivatives |